Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 8/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buformin SCHEMBL15669256 | 0.98 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Buformin SCHEMBL3644254 | 0.98 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Buformin SCHEMBL749659 | 0.98 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Buformin SCHEMBL7999132 | 0.98 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Buformin SCHEMBL6018 | 0.98 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Buformin SCHEMBL1560316 | 0.98 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Buformin SCHEMBL4235633 | 0.96 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Buformin SCHEMBL1048416 | 0.96 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Buformin SCHEMBL22436277 | 0.96 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Buformin SCHEMBL8432153 | 0.96 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11877 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079768-A | Method for selectively and efficiently depolymerizing and recycling PET in waste blended fabric | — | 2026-05-26 | — | — | CN | claimed |
| EP-4499765-B1 | COMPOSITIONS AND METHODS FOR TUNGSTEN ETCHING INHIBITION | BASF SE (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12605354-B2 | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions | NEW FRONTIER LABS, LLC (US) | 2026-04-21 | — | — | US | claimed |
| CN-121586575-A | Metformin oral dosage form and method for preparing the same | 赛乐医药科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20260028334-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2026-01-29 | — | — | US | claimed |
| EP-4684799-A2 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250360215-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | YUH CHIOU HWA (US) | 2025-11-27 | — | — | US | claimed |
| US-20250352497-A1 | BIGUANIDE BASE COMPOSITIONS, BIGUANIDE BASE PHARMACEUTICAL COMPOSITIONS, AND THEIR PREPARATIONS AND USES | ADA FORSYTH INSTITUTE, INC. (US) | 2025-11-20 | — | — | US | claimed |
| US-20250325536-A1 | THERAPEUTIC USES OF GLP1R AGONISTS | VTV THERAPEUTICS LLC (US) | 2025-10-23 | — | — | US | claimed |
| EP-4634964-A1 | SOLUTION FOR POST ETCH RESIDUE REMOVAL (PERR) | BASF SE (DE) | 2025-10-22 | — | — | EP | claimed |
| US-5747527-A | HYPOGLYCEMIC AGENTS FOR TREATMENT OF DIABETES USING EPICACALONE, CACALONE, COMPOUND 3, CACALOL OR DIMATURIN | SHAMAN PHARMACEUTICALS, INC. (US) | 1998-05-05 | — | — | US | claimed |
| WO-1998015266-A1 | USE OF BISPHENOLIC COMPOUNDS TO TREAT TYPE II DIABETES | SHAMAN PHARMACEUTICALS, INC. (US) | 1998-04-16 | — | — | WO | claimed |
| US-5719050-A | Animal cell culturing media containing N-acetyl-L-glutamic acid | EIKEN CHEMICAL CO., LTD. (JP) | 1998-02-17 | — | — | US | claimed |
| US-5691386-A | Triterpenoid compound for the treatment of diabetes | SHAMAN PHARMACEUTICALS, INC. (US) | 1997-11-25 | — | — | US | claimed |
| US-5674900-A | 1,6,9-TRIHYDROXY-1,4,7-TRIMETHYL-4-(4-CARBOXYISODECA-3,7-DIEN -1-YL)-2,3,3A,4,5,7,8,8A-OCTAHYDRO-1H-BENZO(F)INDENE-5,8-DIONE; EXTRACTED FROM PYCNANTHUS; HYPOGLYCEMIC AGENTS | SHAMAN PHARMACEUTICALS, INC. (US) | 1997-10-07 | — | — | US | claimed |
| US-5629319-A | QUINDOLINE ALKALOIDS | SHAMAN PHARMACEUTICALS, INC. (US) | 1997-05-13 | — | — | US | claimed |
| WO-1996039130-A1 | TERPENOID-TYPE QUINONES FOR TREATMENT OF DIABETES | SHAMAN PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1996039401-A1 | FURANOEREMOPHILANE AND EREMOPHILANOLIDE SESQUITERPENES FOR TREATMENT OF DIABETES | SHAMAN PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1996009823-A1 | HYPOGLYCEMIC AGENT FROM CRYPTOLEPIS | SHAMAN PHARMACEUTICALS, INC. (US) | 1996-04-04 | — | — | WO | claimed |
| EP-0659880-A1 | Medium for culturing animal cells or antibody-producing cells | EIKEN CHEMICAL CO., LTD. (JP) | 1995-06-28 | — | — | EP | claimed |